Table 5.
Overall Cohort | |||
---|---|---|---|
n=8004 | |||
Overall Cohort | After chart abstraction | p | |
Serious adverse occurrences | 1306 (16.3, 95%CI 15.5–17.1) | 1317 (16.5, 95%CI 15.6–17.2) | 0.001 |
Deaths | 293 (3.7, 95%CI 3.3–4.1) | 293 (3.7, 95%CI 3.3–4.1) | 1.00 |
FTR | 161 (12.3, 95%CI 10.6–14.2) | 172 (13.1, 95%CI 11.2–15.0) | 0.001 |
Deaths occuring after 48 hours | |||
---|---|---|---|
n=7891 | |||
Overall Cohort | After chart abstraction | p | |
Serious adverse occurrences | 1265 (16.0, 95%CI 15.2–16.9) | 1273 (16.1, 95%CI 15.3–16.9) | 0.002 |
Deaths | 180 (2.2, 95%CI 2.0–2.6) | 180 (2.2, 95%CI 2.0–2.6) | 1 |
FTR | 120 (9.5, 95%CI 7.9–11.2) | 128 (10.1, 95%CI 8.5–11.8) | 0.002 |
Categorical variables expressed as n (%) with 95% exact confidence intervals. P value for McNemar’s test.